Literature DB >> 32109057

Increasing the Cytotoxicity of Ru(II) Polypyridyl Complexes by tuning the Electronic Structure of Dioxo Ligands.

Anna Notaro, Marta Jakubaszek, Nils Rotthowe, Federica Maschietto, Robin Vinck, Patrick S Felder, Bruno Goud, Mickael Tharaud, Ilaria Ciofini, Fethi Bedioui, Rainer F Winter, Gilles Gasser.   

Abstract

Due to the great potential expressed by an anticancer drug candidate previously reported by our group, namely Ru-sq ([Ru(DIP)2(sq)](PF6) (DIP: 4,7-diphenyl-1,10-phenanthroline, sq: semiquinonate ligand), we describe in this work a structure-activity relationship (SAR) that involves a broader range of derivatives resulting from the coordination of different catecholate-like dioxo ligands to the same Ru(DIP)2 core. More in detail, we chose catechols carrying either electron-donating or electron-withdrawing groups EDG or EWG and investigated the physico-chemical and biological properties of their complexes. Several pieces of experimental evidences demonstrated that the coordination of catechols bearing EDGs led to deep red positively charged complexes 1-4 in which the preferred oxidation state of the dioxo ligand is the uninegatively charged semiquinonate. Complexes 5 and 6, on the other hand, are blue/violet neutral complexes which carry an EWG substituted dinegatively charged catecholate ligand. The biological investigation of complexes 1-6 led to the conclusion that the difference in their physico-chemical properties has a strong impact on their biological activity. Thus, complexes 1-4 expressed much higher cytotoxicities than complexes 5 and 6. Complex 1 constitutes the most promising compound of the series and was selected for a more in-depth biological investigation. Apart from its remarkably high cytotoxicity (IC50 = 0.07-0.7 µM in different cancerous cell lines) complex 1 was taken up by HeLa cells very efficiently by a passive transportation mechanism. Moreover, its moderate accumulation in several cellular compartments (i.e. nucleus, lysosomes, mitochondria and cytoplasm) is extremely advantageous in the search of a potential drug with multiple modes of action. Further DNA metalation and metabolic studies pointed to the direct interaction of complex 1 with DNA and to the severe impairment of the mitochondrial function. Multiple targets, together with its outstanding cytotoxicity, make complex 1 a valuable candidate in the field of chemotherapy research. Noteworthy, a preliminary biodistribution study on healthy mice demonstrated the suitability of complex 1 for further in vivo studies.

Entities:  

Year:  2020        PMID: 32109057     DOI: 10.1021/jacs.9b12464

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  8 in total

1.  Light-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells.

Authors:  Olaitan E Oladipupo; Spenser R Brown; Robert W Lamb; Jessica L Gray; Colin G Cameron; Alexa R DeRegnaucourt; Nicholas A Ward; James Fletcher Hall; Yifei Xu; Courtney M Petersen; Fengrui Qu; Ambar B Shrestha; Matthew K Thompson; Marco Bonizzoni; Charles Edwin Webster; Sherri A McFarland; Yonghyun Kim; Elizabeth T Papish
Journal:  Photochem Photobiol       Date:  2021-11-13       Impact factor: 3.421

2.  Biological Investigations of Ru(II) Complexes With Diverse β-diketone Ligands.

Authors:  Raphael T Ryan; Dmytro Havrylyuk; Kimberly C Stevens; L Henry Moore; Sean Parkin; Jessica S Blackburn; David K Heidary; John P Selegue; Edith C Glazer
Journal:  Eur J Inorg Chem       Date:  2021-07-21       Impact factor: 2.551

3.  cis-Locked Ru(II)-DMSO Precursors for the Microwave-Assisted Synthesis of Bis-Heteroleptic Polypyridyl Compounds.

Authors:  Alessio Vidal; Rudy Calligaro; Gilles Gasser; Roger Alberto; Gabriele Balducci; Enzo Alessio
Journal:  Inorg Chem       Date:  2021-04-28       Impact factor: 5.165

4.  An 111In-labelled bis-ruthenium(ii) dipyridophenazine theranostic complex: mismatch DNA binding and selective radiotoxicity towards MMR-deficient cancer cells.

Authors:  Martin R Gill; Michael G Walker; Sarah Able; Ole Tietz; Abirami Lakshminarayanan; Rachel Anderson; Rod Chalk; Afaf H El-Sagheer; Tom Brown; Jim A Thomas; Katherine A Vallis
Journal:  Chem Sci       Date:  2020-08-10       Impact factor: 9.969

5.  A ruthenium-oligonucleotide bioconjugated photosensitizing aptamer for cancer cell specific photodynamic therapy.

Authors:  Luke K McKenzie; Marie Flamme; Patrick S Felder; Johannes Karges; Frederic Bonhomme; Albert Gandioso; Christian Malosse; Gilles Gasser; Marcel Hollenstein
Journal:  RSC Chem Biol       Date:  2021-11-02

6.  Metallodrug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain-like Protease PLpro.

Authors:  Maria Gil-Moles; Sebastian Türck; Uttara Basu; Andrea Pettenuzzo; Saurav Bhattacharya; Ananthu Rajan; Xiang Ma; Rolf Büssing; Jessica Wölker; Hilke Burmeister; Henrik Hoffmeister; Pia Schneeberg; Andre Prause; Petra Lippmann; Josephine Kusi-Nimarko; Storm Hassell-Hart; Andrew McGown; Daniel Guest; Yan Lin; Anna Notaro; Robin Vinck; Johannes Karges; Kevin Cariou; Kun Peng; Xue Qin; Xing Wang; Joanna Skiba; Łukasz Szczupak; Konrad Kowalski; Ulrich Schatzschneider; Catherine Hemmert; Heinz Gornitzka; Elena R Milaeva; Alexey A Nazarov; Gilles Gasser; John Spencer; Luca Ronconi; Ulrich Kortz; Jindrich Cinatl; Denisa Bojkova; Ingo Ott
Journal:  Chemistry       Date:  2021-11-23       Impact factor: 5.020

7.  Photophysical Properties and DNA Binding of Two Intercalating Osmium Polypyridyl Complexes Showing Light-Switch Effects.

Authors:  Mark Stitch; Rayhaan Z Boota; Alannah S Chalkley; Tony D Keene; Jeremy C Simpson; Paul A Scattergood; Paul I P Elliott; Susan J Quinn
Journal:  Inorg Chem       Date:  2022-09-12       Impact factor: 5.436

8.  NIR-Absorbing RuII Complexes Containing α-Oligothiophenes for Applications in Photodynamic Therapy.

Authors:  Liubov M Lifshits; John A Roque; Houston D Cole; Randolph P Thummel; Colin G Cameron; Sherri A McFarland
Journal:  Chembiochem       Date:  2020-09-25       Impact factor: 3.164

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.